DNMT3A mutation was shown to be associated with response to decitabine and azacytidine therapy in myeloid malignancies, and TET2 mutation was associated with the objective response to these DNMT inhibitors in MDS [6, 14]. This evidence concerns the gene TET2 and myelodysplastic syndrome.